½ÃÀ庸°í¼­
»óǰÄÚµå
1575484

Àå¿ë¼º ĸ½¶ ½ÃÀå : ±â´É¼º, Æú¸®¸Ó, ±âÀü, À¯Åë°æ·Î, Åõ¿©2024-11-08°æ·Î, Ä¡·á¿µ¿ªº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Enteric Capsule Market by Functionality, Polymer, Mechanism, Distribution Channel, Route of Administration, Therapeutic Area - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 187 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Àå¿ë¼º ĸ½¶ ½ÃÀåÀº 2023³â 6¾ï 7,453¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 7¾ï 1,332¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¬Æò±Õ 5.81% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 10¾ï 163¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àå¿ë¼º ĸ½¶ ½ÃÀå¿¡´Â À§°¡ ¾Æ´Ñ Àå¿¡¼­ Ȱ¼º Á¦¾à ¼ººÐ(API)ÀÌ ¹æÃâµÇµµ·Ï ¼³°èµÈ Ç¥Àû ¾à¹° Àü´Þ Á¦Ç°ÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ Ä¸½¶Àº À§»êÀ¸·ÎºÎÅÍ ¹Î°¨ÇÑ API¸¦ º¸È£ÇÏ°í ¾àÈ¿¸¦ Çâ»ó½Ã۸ç À§Àå ºÎÀÛ¿ëÀ» ÁÙÀ̱â À§ÇØ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. Ç×»ýÁ¦, È¿¼Ò, ÇÁ·Î¹ÙÀÌ¿Àƽ½º Á¦Á¦ µî ÀǾàǰ¿¡ ±¤¹üÀ§ÇÏ°Ô Àû¿ëµÇ°í ÀÖ½À´Ï´Ù. ÃÖÁ¾ ¿ëµµ´Â ÀǾàǰ°ú °Ç°­º¸Á¶½Äǰ¿¡ Àû¿ëµÇ¸ç, ÁÖ¿ä ºÐ¾ß´Â º´¿ø, Áø·á¼Ò, ¿Â¶óÀÎ ¾à±¹ÀÔ´Ï´Ù. ½ÃÀåÀ» ÁÖµµÇÏ´Â °ÍÀº Ç¥ÀûÈ­µÈ ¾à¹° Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¾à¹° Åõ¿© ¹æ¹ýÀÇ °³¼±ÀÌ ÇÊ¿äÇÑ °í·ÉÈ­, À§Àå °Ç°­¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡ µîÀÔ´Ï´Ù. ĸ½¶ ¼³°è ¹× ¼ÒÀçÀÇ ±â¼úÀû Áøº¸, ƯÈ÷ »ýºÐÇØ¼º ¹× ¹«µ¶¼º ÄÚÆÃÀÇ °³¹ßÀº ¿©·¯ ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. »õ·Î¿î ±âȸ´Â ¸ÂÃãÇü ÀÇ·á¿¡ ÀÖÀ¸¸ç, Àå¿ë¼º ĸ½¶Àº ƯÁ¤ ȯÀÚÀÇ ¿ä±¸¿¡ ¸Â°Ô Á¶Á¤ÇÒ ¼ö Àֱ⠶§¹®¿¡ Á¤¹Ð ¾à¹° Àü´ÞÀÇ ±æÀ» ¿­ ¼ö ÀÖ½À´Ï´Ù. Á¦Á¶¾÷ü°¡ Á÷¸éÇÑ °úÁ¦´Â ³ôÀº ¿øÀÚÀç ºñ¿ë°ú ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°ÇÀ¸·Î ÀÎÇØ ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ Ä¸½¶À» Á¦Á¶Çϱâ À§ÇÑ Àü¹® ÀÎÇÁ¶ó°¡ ÇÊ¿äÇÏ´Ù´Â Á¡µµ Á¦¾àÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦¸¦ ±Øº¹Çϱâ À§ÇØ ±â¾÷µéÀº ¿¬±¸°³¹ß¿¡ ÅõÀÚÇÏ¿© ºñ¿ë È¿À²ÀûÀÎ Á¦Á¶ °øÁ¤À» Çõ½ÅÇϰí, ĸ½¶ Á¦Á¶¸¦ À§ÇÑ »ýºÐÇØ¼º ¼ÒÀ縦 Ž»öÇÒ ¼ö ÀÖ½À´Ï´Ù. °¡Àå À¯¸ÁÇÑ Çõ½Å ºÐ¾ß´Â º¹ÀâÇÑ Ä¡·á ¿ä¹ýÀ» À§ÇØ ¼øÂ÷ÀûÀ¸·Î ¹æÃâµÇ´Â ´Ù¾çÇÑ ¾à¹°À» ´ãÀ» ¼ö ÀÖ´Â ´ÙÁß ±¸È¹ ĸ½¶ÀÇ °³¹ßÀÔ´Ï´Ù. °¡º¯ pH Á¶°Ç¿¡¼­ Àå¿ë¼º ĸ½¶ÀÇ ¾ÈÁ¤¼ºÀ» °³¼±Çϱâ À§ÇÑ ³ª³ë±â¼ú¿¡ ´ëÇÑ Ãß°¡ ޱ¸µµ °æÀï ¿ìÀ§¸¦ °¡Á®¿Ã ¼ö ÀÖ½À´Ï´Ù. ½ÃÀå °æÀïÀº Áß°£ Á¤µµÀ̸ç, ÁÖ¿ä ¾÷üµéÀº ½ÃÀå ÀÔÁö¸¦ È®´ëÇϰí Á¦Ç° ¶óÀξ÷À» °­È­Çϱâ À§ÇØ M&A ¹× Àü·«Àû Á¦ÈÞ¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. Àå¿ë¼º ĸ½¶ ½ÃÀåÀÇ ÀÌÇØ°ü°èÀÚµéÀº ÁøÈ­ÇÏ´Â ¼ÒºñÀÚ ¼ö¿ä ¼Ó¿¡¼­ ¼ºÀåÀ» À¯ÁöÇϱâ À§ÇØ Á¦Ç° Â÷º°È­¿Í ¾ö°ÝÇÑ À§»ý ±ÔÁ¤ Áؼö¿¡ ÁßÁ¡À» µÎ¾î¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ¿¬µµ(2023³â) 6¾ï 7,453¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 7¾ï 1,332¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 10¾ï 163¸¸ ´Þ·¯
CAGR(%) 5.81%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â Àå¿ë¼º ĸ½¶ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Àå¿ë¼º ĸ½¶ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«Àû ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¼¼°è Àα¸ÀÇ À§À庴 ¹× Àå¾ÖÀÇ À¯º´·ü Áõ°¡
    • Á¦¾à¾÷°èÀÇ Àå¿ë¼º ĸ½¶ äÅà Ȯ´ë, Ç¥Àû ¾à¹° Àü´Þ ¹× È¿´É Çâ»ó¿¡ µµ¿ò
    • ´Ù¸¥ ¾à¹° Àü´Þ ¹æ¹ýº¸´Ù °æ±¸ ¾à¹° Åõ¿©¸¦ ¼±È£ÇÏ´Â ¼ÒºñÀÚ Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • °íǰÁú Á©¶óƾ ¹× ±âŸ ¿ø·áÀÇ °¡¿ë¼ºÀÌ Á¦ÇÑµÇ¾î °ø±Þ¸ÁÀÇ Àϰü¼ºÀÌ ¼Õ»óµË´Ï´Ù.
  • ½ÃÀå ±âȸ
    • Àå °Ç°­°ú À£ºùÀ» ¸ñÇ¥·Î ÇÏ´Â ¿µ¾ç º¸ÃæÁ¦ ¿ëµµ¿¡¼­ »ýü ÀÌ¿ë·üÀ» ³ôÀ̱â À§ÇØ Àå¿ë¼º ĸ½¶À» Ȱ¿ëÇÏ´Â ¹æ¹ý
    • Á¦Ç°ÀÇ Ç°Áú°ú ¼º´ÉÀ» Çâ»ó½ÃŰ´Â ĸ½¶ Á¦Á¶ °øÁ¤ÀÇ ±â¼úÀû Áøº¸
    • µ¿¹°¿ë ÀǾàǰ¿¡ Àå¿ë¼º ÄÚÆÃ Ä¸½¶ÀÇ »ç¿ë È®´ë, µ¿¹°¿ë À§Àå¾àÀÇ Àü´Þ ÃÖÀûÈ­
  • ½ÃÀå °úÁ¦
    • º¹ÀâÇÏ°í ½Ã°£ÀÌ ¿À·¡ °É¸®´Â »õ·Î¿î Á¦Á¦ ½ÂÀÎ ÀýÂ÷·Î ÀÎÇØ ½ÅÁ¦Ç° Ãâ½Ã°¡ Áö¿¬µÊ

Portre's Five Forces: Àå¿ë¼º ĸ½¶ ½ÃÀå Ž»öÀ» À§ÇÑ Àü·« µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Àå¿ë¼º ĸ½¶ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ·Â ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Àå¿ë¼º ĸ½¶ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® Àå¿ë¼º ĸ½¶ ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

Àå¿ë¼º ĸ½¶ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º Àå¿ë¼º ĸ½¶ ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Àå¿ë¼º ĸ½¶ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÒ ¼ö ÀÖ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î º¥´õ¸¦ Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àå¿ë¼º ĸ½¶ ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

Àå¿ë¼º ĸ½¶ ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¼¼°è Àα¸ ¼ÒÈ­±â Áúȯ ¹× Àå¾Ö ÀÌȯÀ² Áõ°¡
      • Ç¥Àû ¾à¹°Àü´Þ°ú À¯È¿¼º Çâ»ó ¸ð¾Æ µÎ¾î Á¦¾à ¾÷°è¿¡¼­ Àå¿ë¼º ĸ½¶ äÅÃÀÌ Áõ°¡
      • ±âŸ Åõ¿© ¹æ¹ýº¸´Ù °æ±¸Åõ¿©¸¦ ÁÁ¾ÆÇÏ´Â ¼ÒºñÀÚ°¡ Áõ°¡Çϰí ÀÖ´Ù
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
      • °íǰÁú Á©¶óƾÀ̳ª ±âŸ ¿øÀç·á ÀÔ¼ö°¡ Á¦ÇÑµÇ¾î °ø±Þ¸Á Àϰü¼ºÀÌ ¼Õ»óµÇ°í ÀÖ´Ù
    • ±âȸ
      • Àå °Ç°­°ú À£´Ï½º¸¦ Ÿ°ÙÀ¸·Î ÇÑ ½ÄÀ̺¸ÃæÁ¦ ¿ëµµ¿¡¼­ Àå¿ë¼º ĸ½¶À» Ȱ¿ëÇØ »ýüÀÌ¿ë·üÀ» Çâ»ó½ÃŲ´Ù
      • Á¦Ç° ǰÁú°ú ¼º´ÉÀ» Çâ»ó½ÃŰ´Â ĸ½¶ Á¦Á¶ °øÁ¤ ±â¼úÀû Áøº¸
      • µ¿¹° À§Àå Ä¡·á Åõ¿©¸¦ ÃÖÀûÈ­Çϱâ À§Çؼ­ ¼öÀÇÇÐ Àå¿ë¼º ĸ½¶ »ç¿ëÀ» È®´ëÇÑ´Ù
    • °úÁ¦
      • »õ·Î¿î ó¹æ¿¡ ´ëÇÑ º¹ÀâÇÏ°í ½Ã°£ °É¸®´Â ½ÂÀÎ ÇÁ·Î¼¼½º¿¡ ÀÇÇØ ½ÅÁ¦Ç° ½ÃÀå ÅõÀÔ±îÁö ½Ã°£ÀÌ ´Ê´Â´Ù
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
    • Æú¸®¸Ó À¯Çü : ¿ì¼öÇÑ pHÀÇÁ¸¼º ¿ëÇØ¼º¿¡ ÀÇÇØ ÇÕ¼º Æú¸®¸Ó´Â ³Ð°Ô »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.
    • ¿ëµµ : ¾àÈ¿¸¦ ³ôÀÌ´Â Àå¿ë¼º ĸ½¶ÀÌ ¼±È£µÈ´Ù
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå Àå¿ë¼º ĸ½¶ ½ÃÀå : ±â´É¼ºº°

  • Áö¿¬ ¹æÃâ ĸ½¶
  • ¼ÓÈ¿¼º ĸ½¶
  • ¼­¹æÇü ĸ½¶

Á¦7Àå Àå¿ë¼º ĸ½¶ ½ÃÀå : Æú¸®¸Óº°

  • µ¿¹° À¯·¡
    • Á©¶óƾ
    • shellac
  • ½Ä¹° À¯·¡
    • ¼¿·ê·Î¿À½º ¾Æ¼¼Å×ÀÌÆ® ÇÁÅ»·¹ÀÌÆ®(CAP)
    • ÇÏÀ̵å·Ï½Ã ÇÁ·ÎÆÄÀÏ ¸ÞÆ¿ ¼¿·ê·Î¿À½º(HPMC)
  • ÇÕ¼º À¯·¡
    • Æú¸®(¸ÞŸũ¸±»ê-¸ÞŸũ¸±»ê ¸ÞÆ¿)
    • Æú¸®ÃÊ»êºñ´Ò ÇÁÅ»·¹ÀÌÆ®(PVAP)

Á¦8Àå Àå¿ë¼º ĸ½¶ ½ÃÀå : ¸ÞÄ¿´ÏÁòº°

  • Áö¿¬ ¹æÃâ ĸ½¶
  • ¼­¹æÇü ĸ½¶
  • ¼ÓÈ¿¼º ĸ½¶

Á¦9Àå Àå¿ë¼º ĸ½¶ ½ÃÀå : À¯Åë°æ·Îº°

  • º´¿ø ¾à±¹
  • ¿Â¶óÀÎ ½ºÅä¾î
  • ¼Ò¸Å ¾à±¹

Á¦10Àå Àå¿ë¼º ĸ½¶ ½ÃÀå : Åõ¿© °æ·Îº°

  • °æ±¸
  • Á÷Àå

Á¦11Àå Àå¿ë¼º ĸ½¶ ½ÃÀå : Ä¡·á ¿µ¿ªº°

  • ½ÉÀ庴ÇÐ
  • ´ç´¢º´
  • ¼ÒÈ­±â ³»°ú
  • °¨¿°Áõ
  • ½Å°æÇÐ
  • Á¾¾çÇÐ

Á¦12Àå ¾Æ¸Þ¸®Ä«ÀÇ Àå¿ë¼º ĸ½¶ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦13Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Àå¿ë¼º ĸ½¶ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦14Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Àå¿ë¼º ĸ½¶ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦15Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • ¿¡º¸´ÐÅ©, ÀüÀÓ»ó½ÃÇè¿ë ±â´É¼º °æ±¸ ĸ½¶' EUDRACAP '¸¦ ¹ß¸Å
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • 1. ACG Worldwide
  • 2. Aenova Group
  • 3. Associated Biotech Group
  • 4. Biocaps Enterprises
  • 5. Bright Pharma Caps Inc.
  • 6. Captek Softgel International Inc.
  • 7. Chemcaps Limited
  • 8. Coating Place Inc.
  • 9. Farmacapsulas S.A
  • 10. FUJI Capsule Co., Ltd.
  • 11. GELITA AG
  • 12. GMP Laboratories of America Inc.
  • 13. Hunan ER-Kang Pharmaceutical Co., Ltd.
  • 14. Lonza Group AG
  • 15. Mitsubishi Chemical Holdings Corporation
  • 16. Natural Capsules Limited
  • 17. Nectar Lifesciences Ltd.
  • 18. NextPharma Technologies
  • 19. Qualicaps by Roquette
  • 20. Roxlor LLC
  • 21. Thermo Fisher Scientific Inc.
LSH 24.11.08

The Enteric Capsule Market was valued at USD 674.53 million in 2023, expected to reach USD 713.32 million in 2024, and is projected to grow at a CAGR of 5.81%, to USD 1,001.63 million by 2030.

The enteric capsule market encompasses products designed for targeted drug delivery, ensuring that active pharmaceutical ingredients (APIs) are released in the intestine rather than the stomach. These capsules are crucial for protecting sensitive APIs from stomach acid, enhancing drug efficacy, and reducing gastrointestinal side effects. They are widely applied in pharmaceuticals for medications like antibiotics, enzymes, and probiotic formulations. The end-use scope extends to pharmaceuticals and dietary supplements, with key sectors being hospitals, clinics, and online pharmacies. The market is driven by the escalating demand for targeted drug delivery systems, an aging population necessitating improved drug administration methods, and increased awareness of gastrointestinal health. Technological advancements in capsule design and materials present multiple growth opportunities, particularly in developing biodegradable and non-toxic coatings. An emerging opportunity lies in personalized medicine, where enteric capsules can be tailored for specific patient needs, thus opening avenues for precision drug delivery. A challenge that manufacturers face is the high cost of raw materials and stringent regulatory requirements, which can hinder market growth. Additionally, the need for specialized infrastructure to manufacture these capsules also poses a limitation. To overcome these challenges, businesses can invest in research and development to innovate cost-effective manufacturing processes and explore biodegradable materials for capsule production. The most promising areas of innovation include the development of multi-compartment capsules, which can house different APIs released sequentially for complex therapeutic regimens. Further exploration into nanotechnology for enhanced stability of enteric capsules in variable pH conditions could also offer a competitive edge. The market is moderately competitive, with key players focusing on mergers, acquisitions, and strategic partnerships to expand market presence and enhance product offerings. Stakeholders in the enteric capsule market must emphasize product differentiation and compliance with stringent health regulations to sustain growth amid evolving consumer demands.

KEY MARKET STATISTICS
Base Year [2023] USD 674.53 million
Estimated Year [2024] USD 713.32 million
Forecast Year [2030] USD 1,001.63 million
CAGR (%) 5.81%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Enteric Capsule Market

The Enteric Capsule Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of gastrointestinal diseases and disorders among global population
    • Growing adoption of enteric capsules in pharmaceutical industry for targeted drug delivery and improved efficacy
    • Rising consumer preference for oral drug administration over other delivery methods
  • Market Restraints
    • Limited availability of high-quality gelatin and other raw materials disrupt supply chain consistency
  • Market Opportunities
    • Leveraging enteric capsules for improved bioavailability in nutraceutical applications targeting gut health and wellness
    • Technological advancements in capsule manufacturing processes to enhance product quality and performance
    • Expanding the use of enteric-coated capsules in veterinary medicine to optimize the delivery of gastrointestinal treatments for animals
  • Market Challenges
    • Intricate and time-consuming approval processes for new formulations delay time-to-market for new products

Porter's Five Forces: A Strategic Tool for Navigating the Enteric Capsule Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Enteric Capsule Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Enteric Capsule Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Enteric Capsule Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Enteric Capsule Market

A detailed market share analysis in the Enteric Capsule Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Enteric Capsule Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Enteric Capsule Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Enteric Capsule Market

A strategic analysis of the Enteric Capsule Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Enteric Capsule Market, highlighting leading vendors and their innovative profiles. These include ACG Worldwide, Aenova Group, Associated Biotech Group, Biocaps Enterprises, Bright Pharma Caps Inc., Captek Softgel International Inc., Chemcaps Limited, Coating Place Inc., Farmacapsulas S.A, FUJI Capsule Co., Ltd., GELITA AG, GMP Laboratories of America Inc., Hunan ER-Kang Pharmaceutical Co., Ltd., Lonza Group AG, Mitsubishi Chemical Holdings Corporation, Natural Capsules Limited, Nectar Lifesciences Ltd., NextPharma Technologies, Qualicaps by Roquette, Roxlor LLC, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Enteric Capsule Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Functionality, market is studied across Delayed-Release Capsules, Immediate-Release Capsules, and Sustained-Release Capsules.
  • Based on Polymer, market is studied across Animal Origin, Plant-based, and Synthetic Origin. The Animal Origin is further studied across Gelatin and Shellac. The Plant-based is further studied across Cellulose Acetate Phthalate (CAP) and Hydroxypropyl Methylcellulose (HPMC). The Synthetic Origin is further studied across Poly(methacrylic acid-co-methyl methacrylate) and Polyvinyl Acetate Phthalate (PVAP).
  • Based on Mechanism, market is studied across Delayed-Release Capsules, Extended-Release Capsules, and Immediate-Release Capsules.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Stores, and Retail Pharmacies.
  • Based on Route of Administration, market is studied across Oral and Rectal.
  • Based on Therapeutic Area, market is studied across Cardiology, Diabetes, Gastroenterology, Infectious Diseases, Neurology, and Oncology.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of gastrointestinal diseases and disorders among global population
      • 5.1.1.2. Growing adoption of enteric capsules in pharmaceutical industry for targeted drug delivery and improved efficacy
      • 5.1.1.3. Rising consumer preference for oral drug administration over other delivery methods
    • 5.1.2. Restraints
      • 5.1.2.1. Limited availability of high-quality gelatin and other raw materials disrupt supply chain consistency
    • 5.1.3. Opportunities
      • 5.1.3.1. Leveraging enteric capsules for improved bioavailability in nutraceutical applications targeting gut health and wellness
      • 5.1.3.2. Technological advancements in capsule manufacturing processes to enhance product quality and performance
      • 5.1.3.3. Expanding the use of enteric-coated capsules in veterinary medicine to optimize the delivery of gastrointestinal treatments for animals
    • 5.1.4. Challenges
      • 5.1.4.1. Intricate and time-consuming approval processes for new formulations delay time-to-market for new products
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Polymer Type: Wide use of synthetic polymers owing to their excellent pH-dependent solubility
    • 5.2.2. Applications: Preference for enteric capsules due to their enhancing drug efficacy
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Enteric Capsule Market, by Functionality

  • 6.1. Introduction
  • 6.2. Delayed-Release Capsules
  • 6.3. Immediate-Release Capsules
  • 6.4. Sustained-Release Capsules

7. Enteric Capsule Market, by Polymer

  • 7.1. Introduction
  • 7.2. Animal Origin
    • 7.2.1. Gelatin
    • 7.2.2. Shellac
  • 7.3. Plant-based
    • 7.3.1. Cellulose Acetate Phthalate (CAP)
    • 7.3.2. Hydroxypropyl Methylcellulose (HPMC)
  • 7.4. Synthetic Origin
    • 7.4.1. Poly(methacrylic acid-co-methyl methacrylate)
    • 7.4.2. Polyvinyl Acetate Phthalate (PVAP)

8. Enteric Capsule Market, by Mechanism

  • 8.1. Introduction
  • 8.2. Delayed-Release Capsules
  • 8.3. Extended-Release Capsules
  • 8.4. Immediate-Release Capsules

9. Enteric Capsule Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Stores
  • 9.4. Retail Pharmacies

10. Enteric Capsule Market, by Route of Administration

  • 10.1. Introduction
  • 10.2. Oral
  • 10.3. Rectal

11. Enteric Capsule Market, by Therapeutic Area

  • 11.1. Introduction
  • 11.2. Cardiology
  • 11.3. Diabetes
  • 11.4. Gastroenterology
  • 11.5. Infectious Diseases
  • 11.6. Neurology
  • 11.7. Oncology

12. Americas Enteric Capsule Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Enteric Capsule Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Enteric Capsule Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Evonik launches EUDRACAP preclinic functional oral capsule for preclinical trials
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ACG Worldwide
  • 2. Aenova Group
  • 3. Associated Biotech Group
  • 4. Biocaps Enterprises
  • 5. Bright Pharma Caps Inc.
  • 6. Captek Softgel International Inc.
  • 7. Chemcaps Limited
  • 8. Coating Place Inc.
  • 9. Farmacapsulas S.A
  • 10. FUJI Capsule Co., Ltd.
  • 11. GELITA AG
  • 12. GMP Laboratories of America Inc.
  • 13. Hunan ER-Kang Pharmaceutical Co., Ltd.
  • 14. Lonza Group AG
  • 15. Mitsubishi Chemical Holdings Corporation
  • 16. Natural Capsules Limited
  • 17. Nectar Lifesciences Ltd.
  • 18. NextPharma Technologies
  • 19. Qualicaps by Roquette
  • 20. Roxlor LLC
  • 21. Thermo Fisher Scientific Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦